If you've read anything else on this site, you've probably noticed a pattern: I keep steering the conversation away from the scale. Toward muscle. Toward DEXA scans. Toward what's actually happening underneath the number.
There's a bigger idea underneath all of that, and I think it's worth naming directly: I'm not actually in the business of weight loss. I'm in the business of healthspan.
What I mean by healthspan
Lifespan is how long you live. Healthspan is how many of those years you spend functional, strong, and free of the chronic disease burden that metabolic dysfunction quietly builds over decades. It's a different target than weight loss, and it changes almost everything about how I think about a patient's care.
A patient who loses 40 pounds but loses a significant share of it as muscle, and whose inflammatory markers haven't moved, and whose cardiovascular risk profile looks basically unchanged, has not achieved a healthspan win — even though the scale would tell a very positive story. A patient who loses 25 pounds while preserving lean mass, improving inflammatory markers, and building real strength has achieved something durable, even if the number looks less dramatic.
This is why, in my own tracking of patients, I look well beyond weight and beyond glucose control. Inflammatory markers. Hormonal balance. Cardiovascular indicators. Sleep and recovery. Even cognitive and functional measures. Metabolic disease doesn't stay contained to metabolism — it touches all of these systems, and treating it well means paying attention to more than one number.
Where GLP-1 therapy fits — and where it doesn't
GLP-1 medications are a genuinely important tool for a lot of patients, and I've written about them extensively on this site because they're the most visible part of modern metabolic care right now. But I want to be direct about something: they are one tool, not the whole toolkit.
They're extremely effective at appetite regulation and glucose control. They're not, on their own, a complete answer to inflammation, hormonal decline, muscle preservation, or the other systems that determine whether someone is actually aging well versus just getting smaller. Treating GLP-1 therapy as the entire plan is one of the more common mistakes I see, both from patients and from providers who've adopted these medications without building the rest of the picture around them.
Where peptide therapy fits into this picture
This is where peptide therapies increasingly come in — not as a replacement for GLP-1s or as some separate track, but as an adjunct within a comprehensive plan, used deliberately for patients where they make clinical sense.
I want to be careful and honest about this space, the same way I try to be about everything else on this site. Peptide therapy is a genuinely promising and fast-evolving area, but a meaningful amount of it is still in earlier stages of clinical development than something like GLP-1 therapy, which has now been studied at scale for years. Some peptide compounds have a longer track record and clearer evidence behind specific uses; others are newer, and the honest answer about them is "promising, being studied, not yet fully established." I think patients deserve to hear that distinction clearly rather than have it blurred into one confident-sounding category called "peptides."
What I can say is this: used thoughtfully, as part of an individualized plan and under real clinical supervision, peptide therapy can be a meaningful piece of a comprehensive approach to healthspan — supporting things like tissue repair, inflammation, and recovery in ways that complement, rather than replace, the foundational work of nutrition, muscle preservation, and metabolic management.
What "comprehensive care" actually means in practice
None of this works as a menu where a patient picks a medication and a peptide and calls it done. The patients who do best are the ones whose care is built as a coherent plan: a metabolic therapy suited to their biology, nutrition and training that protects lean mass, peptide support where it's clinically indicated, and ongoing tracking of the markers that actually tell us whether the plan is working — not just whether the scale moved.
That's a more demanding way to practice medicine than writing a single prescription. I think it's the only honest way to actually deliver on healthspan rather than just a lower number on a chart.
What I'd want you to take from this
If you've come to this site because you're curious about GLP-1s, I'd ask you to hold a slightly bigger question alongside that one: not just "will this help me lose weight," but "is my care actually built around my long-term health, or just around one number." Those aren't always the same question, and increasingly, I think the second one is the more important one to be asking.
Curious what a comprehensive, healthspan-focused approach could look like for you? [Reach out / subscribe / etc. — placeholder for your CTA.]
Medical disclaimer: This content is provided for general educational and informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any condition, and it does not create a physician-patient relationship. Every patient's medical history, health status, and treatment needs are different. Always consult your own physician or qualified healthcare provider before starting, stopping, or changing any medication or treatment, and before making any decisions based on information found here. If you are experiencing a medical emergency, call 911 or go to your nearest emergency room.